Pharmaceutical News

RSS

Advertising restrcitions on some over the counter medicines likely to be lifted

Regulations to remove the current ban on advertising certain over the counter (OTC) medicines to the public were laid in Parliament today

9 Jun 2004

Gemcitabine/paclitaxel combination helps breast cancer patients live longer

Breast cancer patients with advanced disease live longer when treated with a new drug, gemcitabine, in combination with paclitaxel, a traditional drug, according to results of a landmark global phase III study

9 Jun 2004

Higher generic drug use in 2003 slowed the rising cost per prescription to a 7.9% increase

Generic drug use increased to a record 48% among Express Scripts' 50 million members during 2003, spurred by the use of several prominent new generics, fluoxetine, omeprazole and lisinopril.

9 Jun 2004

SU11248 proves effective in the treatment of gastrointestinal stromal tumors

A drug originally developed to block the formation of blood vessels in tumors has been shown to overcome resistance to treatment with Gleevec in patients with gastrointestinal stromal tumors (GIST).

9 Jun 2004

Lovastatin and Simvastatin have a significantly reduced risk of prostate cancer

Men who take even small amounts of common cholesterol-lowering drugs such as Lovastatin and Simvastatin have a significantly reduced risk of prostate cancer, according to a new study by Oregon Health & Science University Cancer Institute researchers.

9 Jun 2004

Gene mutation found in some women may decrease effectiveness of tamoxifen breast cancer drug

Researchers from the Johns Hopkins Kimmel Cancer Center, Indiana University and the University of Michigan have found that some women have a gene mutation that may decrease the effectiveness of tamoxifen, a commonly used breast cancer drug.

7 Jun 2004

Chemotherapy regimen more effective and more toxic in Japanese patients than in American patients

A chemotherapy regimen commonly used to treat non-small cell lung cancer is both more effective and more toxic in Japanese patients than in American patients, researchers reported Saturday at the annual meeting of the American Society of Clinical Oncologists.

7 Jun 2004

Atrasentan reduces cancer risk by 20 percent in men with advanced hormone-resistant prostate cancer

Recent clinical studies led by Johns Hopkins Kimmel Cancer Center researchers have found that a drug called atrasentan reduces the risk by 20 percent that cancer will progress in men with advanced hormone-resistant prostate cancer.

7 Jun 2004

A biological agent used without chemotherapy appears to offer a disease-free future to patients with rare leukemia

A biological agent — a drug that wraps vitamin A inside bubbles of fat — used without chemotherapy appears to offer as many as one-third of patients with a rare form of leukemia an opportunity for a long-term, disease-free future, say researchers at The University of Texas M. D. Anderson Cancer Center.

7 Jun 2004

Herceptin shows real promise in treatment of HER-2 positive breast disease

According to a study conducted at The University of Texas M. D. Anderson Cancer Center, more than twice as many women with early stage, HER-2 positive breast disease who received Herceptin as part of their pre-surgery chemotherapy had their tumors completely disappear compared to like patients who received only chemotherapy.

7 Jun 2004

Experimental human monoclonal antibody shows striking benefit in patients with advanced melanoma

Early testing of an experimental human monoclonal antibody showed a striking benefit in patients with advanced melanoma, say researchers at The University of Texas M. D. Anderson Cancer Center, who presented their findings at the annual meeting of the American Society of Clinical Oncology.

7 Jun 2004

Investigational drug, LAF237 improved glycemic control in patients with type 2 diabetes

Research presented today showed that the investigational drug, LAF237, the first in a new class, improved glycemic control in patients with type 2 diabetes. In this study, LAF237, which is administered as a tablet to be taken orally, was added to the standard diabetes treatment metformin in patients whose diabetes was not adequately controlled by metformin alone.

7 Jun 2004

Serum estrogen receptor modulator's (SERM's) may help reduce postmenopausal breast cancer risk

Newest research findings were presented on the possible benefits they may provide for postmenopausal breast cancer risk reduction. SERMs are a class of drugs that can block the cell's ability to use estrogen to stimulate the development of breast cancer.

7 Jun 2004

Treatment with atorvastatin cut incidence of stroke by almost a half

Patients with Type 2 diabetes and a CV risk factor would benefit from a cholesterol-lowering medicine according to results from the first ever specifically designed UK primary prevention statin trial announced today at the American Diabetes Association (ADA)2.

7 Jun 2004

Combination treatment may help type 2 diabetes patients

New research presented by Peter Weissman, M.D., from the University of Miami, at the 64th Annual Scientific Sessions of the American Diabetes Association shows that combination treatment with rosiglitazone maleate and metformin significantly improves certain markers of cardiovascular disease risk in patients with type 2 diabetes compared to metformin alone.

6 Jun 2004

Gemcitabine may help breast cancer patients with advanced disease live longer

6 Jun 2004

Multi-targeted anticancer drug shows promise as treatment for metastatic renal cell cancer

A new multi-targeted anticancer drug called SU11248 has shown very promising results in the treatment for metastatic renal cell cancer, one of the most chemotherapy resistant of all cancers.

6 Jun 2004

Velcade major improvement over standard therapy for relapsed multiple myeloma

Early results from a major, international Phase III clinical trial decisively show that recurrent multiple myeloma is more effectively treated with the drug bortezomib (trade name: Velcade TM) than with dexamethasone, a drug that for decades has been the standard therapy for relapsed disease, researchers at Dana-Farber Cancer Institute report.

6 Jun 2004

Exenatide shows significant improvements in glucose control for people With type 2 diabetes

Amylin Pharmaceuticals, Inc., and Eli Lilly and Company have presented detailed 30-week data from two of the three pivotal Phase 3 studies of exenatide during a late-breaking session at the American Diabetes Association's (ADA) 64th Scientific Sessions in Orlando, Florida.

5 Jun 2004

60,000 set to run in race for the cure

Participants at the Susan G. Komen Breast Cancer Foundation National Race for the Cure® were among the first to view a new breast cancer ribbon today as they descended on the National Mall.

5 Jun 2004

Pharmaceutical News

Advertising restrcitions on some over the counter medicines likely to be lifted

Gemcitabine/paclitaxel combination helps breast cancer patients live longer

Higher generic drug use in 2003 slowed the rising cost per prescription to a 7.9% increase

SU11248 proves effective in the treatment of gastrointestinal stromal tumors

Lovastatin and Simvastatin have a significantly reduced risk of prostate cancer

Gene mutation found in some women may decrease effectiveness of tamoxifen breast cancer drug

Chemotherapy regimen more effective and more toxic in Japanese patients than in American patients

Atrasentan reduces cancer risk by 20 percent in men with advanced hormone-resistant prostate cancer

A biological agent used without chemotherapy appears to offer a disease-free future to patients with rare leukemia

Herceptin shows real promise in treatment of HER-2 positive breast disease

Experimental human monoclonal antibody shows striking benefit in patients with advanced melanoma

Investigational drug, LAF237 improved glycemic control in patients with type 2 diabetes

Serum estrogen receptor modulator's (SERM's) may help reduce postmenopausal breast cancer risk

Treatment with atorvastatin cut incidence of stroke by almost a half

Combination treatment may help type 2 diabetes patients

Gemcitabine may help breast cancer patients with advanced disease live longer

Multi-targeted anticancer drug shows promise as treatment for metastatic renal cell cancer

Velcade major improvement over standard therapy for relapsed multiple myeloma

Exenatide shows significant improvements in glucose control for people With type 2 diabetes

60,000 set to run in race for the cure

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News